Merck: positive data in urothelial cancer
(CercleFinance.com) - Merck announces that the KEYNOTE-A39/EV-302 trial has met its primary endpoints of overall survival (OS) and progression-free survival (PFS) in selected patients with previously untreated locally advanced or metastatic urothelial cancer.
Initial results from this Phase III study show that the Keytruda-Padcev combination achieved statistically significant and clinically meaningful improvements in OS, PFS and the key secondary endpoint of overall response rate, compared with chemotherapy.
Merck, in collaboration with Seagen and Astellas, is evaluating this combination as part of an extensive clinical development program in urothelial cancer, including two Phase III clinical trials in muscle-invasive bladder cancer.
Copyright (c) 2023 CercleFinance.com. All rights reserved.